SAPIEN 3: Good Outcomes in Bicuspids

Courtesy of Dr. Carlos Fava.

Bicuspid aortic valves are found in approximately 2% of patients and represent the most frequent cause of aortic stenosis in young adults requiring valve replacement.

La SAPIEN 3 presenta buenos resultados en las bicúspides

Though TAVR has advanced significantly, this entity has not yet been included in the different randomized studies. At present, we have data from different reports, but no consolidation.

The study looked at the STS/ACC Registry, which included patients receiving the percutaneous valve SAPIEN 3 between June 2015 and November de 2018.

This analyzis included 81822 patients: 2726 presented bicuspid aortic valve (3.33%); the rest were tricuspid.

Bicuspid patients were more often men, younger, with fewer comorbidities and lower STS mortality score. After Propensity Score Matching, 2691 patients were left in each group, with mean age 74, 60% men and 4.9% STS.


Read also: AHA 2019 | Sapien vs Evolut: A Head-to-Head Study Seems Mandatory.


Bicuspid patients required a larger valve, regardless implantation or procedural success. At hospital level, there were no differences in mortality, but conversion to surgery, annulus rupture and stroke were more frequent in bicuspid patients.

At 30 days, there were no differences in mortality. In addition, there were elevated risks of stroke (2.5% vs 1.6%; absolute RD,0.89% [95% CI, 0.88% – 0.9%]; HR, 1.57 [95% CI, 1.06 – 2.33]) and definite pacemaker (9.1% vs 7.5%; absolute RD, 1.65% [95% CI, 1.63%-1.66%]; HR, 1.23 [95% CI, 1.02-1.49]) in bicuspid patients.

At one year, there were no differences in mortality or stroke in both groups.


Read also: TCT 2019 | Mitral Valve-in-Valve: 1-Year Results for Sapien 3 in Mitral Valve Replacement for Degenerated Bioprostheses.


There were no differences in valve hemodynamics profile at 30 days and one year in area, gradient or moderate to severe regurgitation.

Both groups improved functional class.

Conclusion

In this registry of propensity score matched patients, those receiving transcatheter aortic valve replacement for severe aortic stenosis in bicuspid or tricuspid valves showed no differences at 30 days and one year in mortality. However, there was increased stroke in bicuspid valve patients.

Given the potential bias in patient selection and the absence of a control group, these outcomes call for further study to better determine the safety and efficacy of transcatheter aortic valve replacement in bicuspid patients.

Courtesy of Dr. Carlos Fava.

Original Title: Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke.

Reference: Raj R. Makkar, et al. JAMA. 2019;321(22):2193-2202. doi:10.1001/jama.2019.7108.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...